ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health. In addition, the company provides contract manufacturing services of OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone215-345-0919
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.87 million
Profitability
Miscellaneous
Employees44
Next Earnings DateN/A
OptionableNot Optionable
ProPhase Labs (NASDAQ:PRPH) Frequently Asked Questions
What is ProPhase Labs' stock symbol?
ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."
How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?
ProPhase Labs announced a special dividend on Thursday, December 27th. Stockholders of record on Thursday, January 10th will be paid a dividend of $0.25 per share on Thursday, January 24th. The ex-dividend date of this dividend is Wednesday, January 9th. View ProPhase Labs' Dividend History.
How will ProPhase Labs' stock buyback program work?
ProPhase Labs announced that its Board of Directors has initiated a stock buyback program on Saturday, November 11th 2017, which authorizes the company to buyback 1,700,000 shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through a tender offer. Stock buyback programs are often a sign that the company's board of directors believes its stock is undervalued.
How were ProPhase Labs' earnings last quarter?
ProPhase Labs Inc (NASDAQ:PRPH) issued its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $2.44 million for the quarter. ProPhase Labs had a negative net margin of 11.41% and a negative return on equity of 4.87%. View ProPhase Labs' Earnings History.
Has ProPhase Labs been receiving favorable news coverage?
Media headlines about PRPH stock have been trending negative on Thursday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ProPhase Labs earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future.
Who are some of ProPhase Labs' key competitors?
Some companies that are related to ProPhase Labs include CytoDyn (CYDY), PhaseBio Pharmaceuticals (PHAS), Chiasma (CHMA), AgeX Therapeutics (AGE), China SXT Pharmaceuticals (SXTC), ASLAN PHARMACEU/ADR (ASLN), Sierra Oncology (SRRA), Newron Pharmaceuticals (NWPHF), Unum Therapeutics (UMRX), Galmed Pharmaceuticals (GLMD), Aptinyx (APTX), Correvio Pharma (CORV), Harrow Health (HROW), Eton Pharmaceuticals (ETON) and Zynerba Pharmaceuticals (ZYNE).
What other stocks do shareholders of ProPhase Labs own?
Who are ProPhase Labs' key executives?
ProPhase Labs' management team includes the folowing people:
- Mr. Ted William Karkus, Chairman & CEO (Age 60)
- Ms. Monica Brady, CFO & Chief Accounting Officer (Age 42)
Who are ProPhase Labs' major shareholders?
ProPhase Labs' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (0.12%), Dimensional Fund Advisors LP (0.09%) and Dimensional Fund Advisors LP (0.09%). Company insiders that own ProPhase Labs stock include Braden Michael Leonard, Jason Michael Barr, Robert V Cuddihy Jr and Ted William Karkus. View Institutional Ownership Trends for ProPhase Labs.
Which major investors are selling ProPhase Labs stock?
Which major investors are buying ProPhase Labs stock?
How do I buy shares of ProPhase Labs?
Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProPhase Labs' stock price today?
One share of PRPH stock can currently be purchased for approximately $3.22.
How big of a company is ProPhase Labs?
ProPhase Labs has a market capitalization of $37.19 million and generates $9.87 million in revenue each year. ProPhase Labs employs 44 workers across the globe.
What is ProPhase Labs' official website?
How can I contact ProPhase Labs?
ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]
MarketBeat Community Rating for ProPhase Labs (NASDAQ PRPH)
MarketBeat's community ratings are surveys of what our community members think about ProPhase Labs and other stocks. Vote "Outperform" if you believe PRPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
